Results 241 to 250 of about 174,708,283 (296)

Letermovir in Refractory and Resistant CMV After Lung Transplantation: Therapeutic Potential and Emergence of Resistance

Transplant Infectious Disease, EarlyView.
Letermovir use for active R/R CMV infection was associated with treatment‐emergent resistance in approximately one‐third of patients, particularly in those with high baseline viral loads and delayed virological response. These findings support careful patient selection, close virological monitoring, and early resistance testing.
Tobias Veit, Stefan Trost, Teresa Kauke, Nina Engels, Gabriela Leuschner, Michael Gerckens, Carlo Mümmler, Sebastian Michel, Michael Zoller, Valeria Hackemann, Jürgen Behr, Nikolaus Kneidinger   +11 more
wiley   +1 more source

Leptin protects chondrocytes by inhibiting autophagy via phosphoinositide 3 kinase/protein kinase B/mammalian target of rapamycin signaling pathway. [PDF]

Heliyon
Li P, Jiang W, Yang Q, Lu Y, Zhang J.
europepmc   +1 more source

Association between serum branched chain amino acids, mammalian target of rapamycin levels and the risk of gestational diabetes mellitus: a 1:1 matched case control study. [PDF]

BMC Pregnancy Childbirth
Cui L, Li Z, Liu X, Li Z, Li J, Guo Y, Zhou H, Yang X, Zhang Z, Gao Y, Ren L, Hua L.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Inhibitors of the Mammalian Target of Rapamycin

Expert Opinion on Investigational Drugs, 2005
The mammalian target of rapamycin (mTOR) is a downstream protein kinase of the phosphatidylinositol 3'-kinase-Akt signalling pathway. As a result of its position within this pathway and its central role in controlling cellular growth, mTOR is viewed as an important target for anticancer therapeutics development. Currently, the mTOR inhibitor rapamycin (
Janet Dancey
exaly   +3 more sources

Mammalian Target of Rapamycin as a Therapeutic Target in Oncology

Expert Opinion on Therapeutic Targets, 2008
The mammalian target of rapamycin (mTOR) has emerged as a validated therapeutic target in cancer and mTOR inhibitors alter tumor cell responses to mitogenic signals and microenvironmental stress.The aims of this review are to describe the mTOR signaling pathway and the rationale for the use of rapamycin analogs and other mTOR inhibitors for oncology ...
Robert T Abraham, Christina H Eng
exaly   +3 more sources

Mammalian target of rapamycin

Seminars in Oncology, 2004
Targeted molecular therapeutics are tailored toward the genetic abnormalities that cause tumor progression. Modulation of certain signaling pathways that are aberrant in cancer cells has the potential to provide an effective, nontoxic approach to therapy in a broad range of cancers. Agents targeting BCR-ABL (imatinib mesylate [formerly known as STI-571]
Funda, Meric-Bernstam, Gordon B, Mills
openaire   +2 more sources

Targeting the mammalian target of rapamycin in myxoid chondrosarcoma

Anti-Cancer Drugs, 2008
Myxoid chondrosarcoma is a slow-growing sarcoma poorly responsive to chemotherapy and radiation therapy. Translational research has validated several proteins as optional therapeutic targets. Significant responses are, however, rare. In this paper we report an extraordinary response of myxoid chondrosarcoma to targeted therapy by rapamycin in ...
Ofer, Merimsky, Rinat, Bernstein-Molho, Ronit, Sagi-Eisenberg   +2 more
openaire   +2 more sources

Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

Current Molecular Medicine, 2005
Reflecting its critical role in integrating cell growth and division with the cellular nutritional environment, the mammalian target of rapamycin *(mTOR) is a highly conserved downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway. mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the
Francis J, Giles, Maher, Albitar
openaire   +2 more sources

Mammalian target of rapamycin as a target in hematological malignancies

Targeted Oncology, 2011
The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway
Kevin R, Kelly, Julie H, Rowe, Swaminathan, Padmanabhan, Steffan T, Nawrocki, Jennifer S, Carew   +4 more
openaire   +2 more sources